Earnings Feed
Sign Up
Home/Filings/4/0001144204-13-034154
4//SEC Filing

Baker/Tisch Investments, LP 4

Accession 0001144204-13-034154

CIK 0000911326other
View on SEC.govCompany Profile

Filed

Jun 9, 8:00 PM ET

Accepted

Jun 10, 5:17 PM ET

Size

40.1 KB

Accession

0001144204-13-034154

Insider Transaction Report

Form 4
Period: 2013-06-06
SYNAGEVA BIOPHARMA CORPGEVA
BAKER FELIX
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
BAKER JULIAN
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Baker Bros. Investments II, L.P.
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
667, L.P.
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Baker Biotech Fund II (A), L.P.
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
BAKER BROS. ADVISORS LP
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Baker Brothers Life Sciences LP
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Baker Bros. Investments, L.P.
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
14159, L.P.
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Baker/Tisch Investments, LP
Director10% Owner
Transactions
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2013-06-06+15,000→ 15,000 total(indirect: See footnote)
    Exercise: $40.32Exp: 2023-06-06→ Common Stock (15,000 underlying)
Footnotes (9)
  • [F1]7,500 non-qualified stock options ("Stock Options")convertible solely into Common Shares granted to Felix J. Baker and 7,500 Stock Options granted to Dr. Stephen R. Biggar, a Partner of Baker Bros. Advisors, LLC (the "Adviser")pursuant to the Issuer's 2005 Stock Plan. The Stock Options with a strike price of $40.32 vest in twelve equal monthly installments beginning on June 6, 2013. Felix J. Baker and Dr. Stephen R. Biggar serve on the Issuer's Board of Directors (the "Board") as a representative of Baker Bros. Investments, L.P. ("Bros I"), Baker Bros. Investments II, L.P. ("Bros II"), Baker Tisch Investments, L.P. ("Baker Tisch"), 667, L.P. ("667"), Baker Biotech Fund II(A), L.P. ("Biotech IIA"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P.("14159", and together with Bros I, Bros II, Baker Tisch, 667, Biotech IIA, and Life Sciences, the "Funds"). Pursuant to the policies of the Adviser, Felix J. Baker and Julian C. Baker do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds, were entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options (i.e. no direct pecuniary interest).
  • [F2]As a result of their ownership interest in Baker Bros. Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by Bros I, a limited partnership of which the sole general partner is Baker Bros. Capital, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC, due to Baker Bros. Capital, L.P.'s right to receive an allocation of a portion of the profits from Bros I.
  • [F3]As a result of their ownership interest in Baker Bros. Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by Bros II, a limited partnership of which the sole general partner is Baker Bros. Capital, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC, due to Baker Bros. Capital, L.P.'s right to receive an allocation of a portion of the profits from Bros II.
  • [F4]As a result of their ownership interest in Baker Tisch Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by Baker Tisch, a limited partnership of which the sole general partner is Baker Tisch Capital, L.P., a limited partnership of which the sole general partner is Baker Tisch Capital (GP), LLC, due to Baker Tisch Capital, L.P.'s right to receive an allocation of a portion of the profits from Baker Tisch.
  • [F5]As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • [F6]As a result of their ownership interest in Baker Biotech Capital II(A) (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by Biotech IIA, a limited partnership of which the sole general partner is Baker Biotech Capital II(A), L.P., a limited partnership of which the sole general partner is Baker Biotech Capital II(A) (GP), LLC, due to Baker Biotech Capital II(A), L.P.'s right to receive an allocation of a portion of the profits from Biotech IIA.
  • [F7]As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  • [F8]As a result of their ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 15,000 options to purchase the Common Stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
  • [F9]The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Julian C. Baker and Felix J. Baker are principals of the Adviser. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Julian C. Baker, Felix J. Baker and/or the Adviser are beneficial owners of such securities for purposes of Section 16 or any other purpose.

Documents

1 file

Issuer

SYNAGEVA BIOPHARMA CORP

CIK 0000911326

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001551137

Filing Metadata

Form type
4
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 5:17 PM ET
Size
40.1 KB
View on SEC.gov